Department of Medical Epidemiology and Biostatistics, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2469-78. doi: 10.1158/1055-9965.EPI-10-0424. Epub 2010 Jul 29.
The link between squamous cell cervical carcinoma and human papillomavirus (HPV) 16/18 is well established, but the magnitude of the risk association is uncertain and the importance of other high-risk HPV (HRHPV) types is unclear.
In two prospective nested case-control series among women participating in cytologic screening in Sweden, we collected 2,772 cervical smears from 515 women with cancer in situ (CIS), 315 with invasive squamous cell carcinoma (SCC), and individually matched controls. All smears were tested for HPV with PCR assays, and the median follow-up until diagnosis was 5 to 7 years. Conditional logistic regression was used to estimate relative risks (RR) and 95% confidence intervals (95% CI).
The presence of HPV16/18 in the first smear was associated with 8.5-fold (95% CI, 5.3-13.7) and 18.6-fold (95% CI, 9.0-38.9) increased risks of CIS and SCC, respectively, compared with women negative for HPV. Infection with other HRHPV types in the first smear was also associated with significantly increased risks for both CIS and SCC. Persistence of HPV16 infection conferred a RR of 18.5 (95% CI, 6.5-52.9) for CIS and 19.5 (95% CI, 4.7-81.7) for SCC. The HPV16/18 attributable risk proportion was estimated at 30% to 50% for CIS, and 41% to 47% for SCC. Other HRHPV types also conferred significant proportions.
Our large population-based study provides quantification of risks for different HPV types and prospective evidence that non-16/18 HRHPV types increase the risk for future cervical cancer.
This study gives further insights into cervical cancer risk stratification with implications for HPV-based prevention strategies.
人乳头瘤病毒(HPV)16/18 与宫颈鳞癌之间的关联已得到充分证实,但风险关联的程度仍不确定,其他高危型 HPV(HRHPV)的重要性尚不清楚。
在瑞典细胞学筛查的女性中进行的两项前瞻性巢式病例对照系列研究中,我们从 515 例原位癌(CIS)、315 例浸润性鳞状细胞癌(SCC)患者和个体匹配的对照者中收集了 2772 份宫颈涂片。所有涂片均采用 PCR 检测 HPV,并在诊断前进行 5 至 7 年的中位随访。采用条件 logistic 回归估计相对风险(RR)和 95%置信区间(95%CI)。
首次涂片时 HPV16/18 的存在与 CIS 和 SCC 的风险分别增加 8.5 倍(95%CI,5.3-13.7)和 18.6 倍(95%CI,9.0-38.9),与 HPV 阴性的女性相比。首次涂片时感染其他 HRHPV 类型也与 CIS 和 SCC 的风险显著增加相关。HPV16 持续感染与 CIS 的 RR 为 18.5(95%CI,6.5-52.9),与 SCC 的 RR 为 19.5(95%CI,4.7-81.7)。HPV16/18 的归因风险比例估计为 CIS 的 30%至 50%,SCC 的 41%至 47%。其他 HRHPV 类型也有显著的比例。
我们的大型基于人群的研究提供了不同 HPV 类型风险的定量评估,并提供了前瞻性证据表明非 16/18 HRHPV 类型增加了未来宫颈癌的风险。
这项研究进一步深入了解宫颈癌风险分层,对基于 HPV 的预防策略具有重要意义。